History
The ambitious pursuit of innovation
MicroPort® was founded in 1998 in a small office in ZJ Hi-Tech Park in Shanghai, by a group of dedicated individuals who shared the belief that advancements in medical technology could transform patients’ lives. This core belief has driven us to constantly innovate through a super-conglomerate of people-centric enterprises.
Today, we can proudly say that – over the last 25 years – we have been breaking barriers and accelerating access to life-changing technologies. This purpose is what is driving us to continue seeking partnerships and collaborations with healthcare professionals and medical societies to foster innovation that could transform medical treatments, so patients everywhere can enjoy better and longer lives.
MicroPort NeuroTech was listed on the Main Board of the Hong Kong Stock Exchange
MicroPort MedBot Skywalker™ Orthopedic Surgical Robot received NMPA approval in China, FDA 510(k) approval in the US and CE mark approval in Europe
MicroPort NeuroTech Diveer® Intracranial Balloon Catheter, Neurohawk® Stent Thrombectomy Device, X-track® Intracranial Distal Access Catheter, and NUMEN Silk® 3D Electronically Detachable Coil received NMPA approvals in China
MicroPort MedBot Toumai® Laparoscopic Surgical Robot received NMPA approval in China and won several awards
MicroPort® CRM Invicta™ Defibrillation leads received CE mark approval in Europe
MicroPort Endovascular Talos® Thoracic Stent Graft System received NMPA approval in China
MicroPort Urocare Single-use Flexible Digital Ureteroscope received the NMPA approval in China
MicroPort Argus™ intravascular OCT system received NMPA approval in China
MicroPort® inaugurated a training Center in Brazil
MicroPort® CardioFlow Medtech was listed on the Main Board of the Hong Kong Stock Exchange
MicroPort® MedBot® was listed on the Main Board of the Hong Kong Stock Exchange
MicroPort® CRM introduced the Alizea™ and Borea™ pacemakers equipped with Bluetooth technology and the SmartView Connect™ home monitor in Europe.
MicroPort® CRM Navigo™ left ventricular pacing leads received CE mark approval in Europe
MicroPort NeuroTech™ U-track Intracranial Support Catheter System became commercially available in the market
EverPace Disposable Cardiac Mapping Leads became commercially available in the market
Firefighter™ and Foxtrot® Pro PTCA Balloon Dilatation Catheter approved for marketing in Pakistan and Bosnia and Herzegovina
HorizonMedical™ Daylily® Embryo Transfer Catheter approved for marketing in Thailand
Four products including Firehawk® Stent and Firefighter™ PTCA Balloon Dilatation Catheter received registration and marketing approval in Saudi Arabia
Firefighter™ NC received registration approval in Taiwan.
The MicroPort Group and its associated companies introduced external financing of over US$1 billion accumulatively and widely recognized by the capital market.
MicroPort® and NDR, a developer of automated needle targeting Robotics systems, announced strategic investment and agreement to establish a joint venture in China
MicroPort® and Robocath, a vascular interventional robot company, reached a strategic investment agreement and signed a binding framework agreement for the establishment of a joint venture in China
MicroPort® and Siemens Healthcare reached a strategic cooperation agreement on medical angiography X-ray machines
MicroPort® strategically invested in an Indian medical device company, Purple Medical, and established a joint-venture company
MicroPort® (00853.HK) was included in the MSCL Hong Kong Index
MicroPort® (00853.HK) was included in the Hang Seng Composite Mid-Cap Index and Large Mid-Cap Index and officially entered the Shanghai-Hong Kong Stock Connect
MicroPort® Orthopedics' first domestic total hip replacement system was approved for marketing
MicroPort® NeuroTech Numen® System was approved for China Domestic Market
MicroPort® announced the results of a 3-year clinical study of Firehawk® TARGET AC stents, first announced at EuroPCR, further confirming the long-term safety and efficacy of the world’s lowest drug-loaded coronary drug stents
Initiated “1+12+5” operating model and began exponential growth
SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China.
MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System.
The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be published in the Journal of the American College of Cardiology (JACC).
Every 6 seconds, a MicroPort® product was used across the world.
Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet.
Tubridge® Vascular Reconstruction Device was launched.
Firehawk® and Firebird2® gained regulatory approval in Taiwan.
First implantation of Rega® Family Implantable Pacemakers.
Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively.
MicroPort® CRM global headquarter was established in Clamart, France.
MicroPort Orthopedics (Suzhou) Co., Ltd. was established.
Every 12 seconds, a MicroPort® product was used across the world.
Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash.
AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award.
Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval.
The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0.
Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study.
Firesorb® pivotal study FUTURE II trial completed first enrollment.
MicroPort® CardioFlow brought in strategic investors.
MicroPort® EP quoted on NEEQ.
MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors.
MicroPort® Jiaxing park established.
Acquired Brazil distributors to implement localized management on the Brazil market.
New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award.
Columbus® 3D EP Navigation System received CFDA approval.
MicroPort Scientific India Private Ltd. Established.
MicroPort® Suzhou park established.
Annual sales exceeded 3 billion HKD.
Every 15 seconds, a MicroPort® product was used across the world.
MicroPort® Innovation Platform won State Science and Technology Advancement Award.
Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark.
EVOLUTION® medial-pivot knee system received CFDA approval.
MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line.
MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone.
MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established.
Every 18 seconds, a MicroPort® product was used across the world.
Firehawk® rapamycin target eluting coronary stent system received CFDA approval.
WILLIS® clinical application project won State Science and Technology Advancement Award.
Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business.
Acquired drug eluting stent related assets and intellectual properties from Cordis.
Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park.
Annual sales exceeded 2 billion RMB.
Every 20 seconds, a MicroPort® product was used across the world.
MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA.
Globalization Strategy Implemented.
Every 20 seconds, a MicroPort® product was used across the world.
Initiated “10+5” Operating Model.
Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established.
Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.
Every 20 seconds, a MicroPort® product was used across the world.
MicroPort Medical (Jiaxing) Co., Ltd. was established.
Undertook national R&D projects accumulating to more than 100 million RMB.
Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.
Every 18 seconds, a MicroPort® product was used across the world.
MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK).
Annual sales exceeded 100 million USD.
Shanghai MicroPort EP MedTech Co., Ltd. was established.
Firebird2™ coronary drug-eluting stent system received registration approval from SFDA.
Shanghai MicroPort Orthopedics Co., Ltd. was established.
Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented.
Began experimental implementation of "Vertical Integration & Horizontal Connection" management model.
Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award.
Hercule® Thoracic Stent-Graft System received SFDA approval.
Coronary drug eluting stent implants reached over 100,000 units.
Aegis Bifurcated Stent-Graft System was named National key new product.
Annual sales exceeded 100 million RMB.
Firebird™ drug eluting stent system received SFDA approval.
Mustang™ coronary stent system received CE mark.
Officially entered Japan market with PTCA Balloon dilatation catheters.
Received major funding from National Development and Reform Commission.
Moved into new headquarters at 501 Newton Road, Zhangjiang Hi-Tech Park.
Received "Shanghai Hi-Tech Enterprise" honor and business became profitable.
Mustang™ bare metal stent received SFDA approval.
PTCA balloon dilatation catheter received SFDA approval, very first sale made.
Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai.